The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...

Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...

AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...

Idorsia, which is no stranger to needing to find cash quickly, also said it has raised 150 million Swiss francs ($167 million ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) ...